Luke Exam

Within the paper, major Lukan themes are portrayed. The birth narrative is reimagined with major themes of the narrative, especially the purpose of the birth narrative to Theophilus, Luke\u27s mentor. The paper defines and identifies Christology and discipleship which is formed from Luke. The paper illustrates what Jesus really means by stating the first century was an evil and adulterous generation (Luke 9:41). The essay concludes with the passion narrative and personal challenges that I have faced as studying the book of Luke

The Developmental Test Scheduling Problem

Developmental testing of aircraft systems in the United States Air Force requires a complex set of resources for each test. The optimal scheduling of those resources is the job of the 412th Test Wing at Edwards Air Force Base. With more than 20 different Combined Task Forces requesting resources for roughly 300 flying missions each week, manual scheduling is a difficult task. The current process takes a team of schedulers several days to get a workable result from which they can start tailoring the final schedule. While concepts and techniques can be taken from industry scheduling problems, the body of knowledge as it relates to developmental test scheduling is sparse. The contribution of this paper is to initially document the Developmental Test Scheduling Problem, define it in structured terms for which a solution methodology can be designed, and present an Integer Programming based solution. The design allows for a scheduler to tailor an initial answer to fit nuanced and timely objectives and constraints. For this prototype effort the problem is scoped to the Iron Resources while bearing in mind the extensibility of the approach to Range Resources. This study and prototype will demonstrate results that will create an initial schedule in several hours and serve as a good starting point for the final schedule

So, how are the children?

Since her arrival at Concordia in 1978, Professor Emerita of Education Dr. Barbara Schoenbeck established a well-deserved reputation as an outstanding educator, a compassionate and influential mentor, a cherished colleague, and a humble, inspirational servant-leader passionately driven to promote positive, inclusive social change. Dr. Schoenbeck served Concordia St. Paul with distinction for twenty-seven years before her retirement in 2005, but has continued playing an essential role in Concordia’s graduate program and as supervisor of practicum students and student teachers. Her unparalleled dedication to the church, community, and to social justice, has been an inspiration to generations of students, staff, and faculty

Updated perspectives on the management of multiple myeloma in older patients: Focus on lenalidomide

Multiple myeloma is a hematologic malignancy that predominantly affects older adults, with a median age at diagnosis of 70 years old. A mainstay of multiple myeloma treatment is lenalidomide, which is an immunomodulatory drug (IMiD) that changed the treatment paradigm for multiple myeloma. This is particularly true for older adults who do not undergo autologous stem cell transplantation (ASCT). Several pivotal trials summarized in this review demonstrate the efficacy and safety of lenalidomide in older adults with multiple myeloma, including significant improvements in response rates, progression-free survival and overall survival in the first-line and relapsed/refractory settings. Potential adverse effects include venous thromboembolism, cytopenias, and second malignancies and the doses tolerated in real-world older patients are often lower than those utilized in clinical trials enrolling select older patients. Given the heterogeneity of aging, several approaches to measuring frailty have been developed and validated to aid in predicting which older adults may benefit from empiric dose reduction to reduce the risk of toxicity and improve the tolerability of treatment. A number of randomized trials have explored a range of approaches utilizing lenalidomide in older adults in both the up-front and relapsed setting, ranging from attenuated maintenance strategies through quadruplet combination therapies including proteasome inhibitors and monoclonal antibodies. This wealth of literature provides a great number of options, which can make it difficult for a clinician to determine a single optimal recommendation for an individual patient. While lenalidomide is currently part of standard of care, the treatment of multiple myeloma is growing rapidly. There is a need to expand clinical trials participation to older adults with multiple myeloma. Incorporation of validated comprehensive geriatric assessments in clinical trials for multiple myeloma could provide a more accurate depiction of the older patient population and is an area for future exploration